Results 21 to 30 of about 798,481 (288)
Frontiers in Oncology, 2020 Glioblastoma (GB) is the most malignant and aggressive form of brain tumor, characterized by frequent hyperactivation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway.
Qin Xia +5 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Background: Mammalian target of rapamycin (mTOR) inhibitors, such as everolimus and sirolimus, may be efficacious in preserving renal function in liver transplantation (LT) recipients while preventing hepatocellular carcinoma (HCC) recurrence.Materials ...
Pil Soo Sung +17 more
doaj +1 more source
Targeting mTOR for cancer therapy
Journal of Hematology & Oncology, 2019 Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. mTOR is usually assembled into several complexes such as mTOR complex 1/2 (mTORC1/2).
Hui Hua +5 more
doaj +1 more source
mTOR inhibitors potentially reduce TGF-β2-induced fibrogenic changes in trabecular meshwork cells
Scientific Reports, 2021 We examined the effects of mTOR inhibitors on the fibrotic response induced by transforming growth factor-beta2 (TGF-β2) in cultured human trabecular meshwork (hTM) cells. TGF-β2-induced expression of fibronectin, collagen type I, alpha 1 chain (COL1A1),
Nozomi Igarashi +2 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background The clinical characteristics of mTOR (mammalian target of rapamycin) inhibitors use in heart transplant recipients and their outcomes have not been well described.
Polydoros N. Kampaktsis +11 more
doaj +1 more source
Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines. [PDF]
PLoS ONE, 2015 The mammalian target of rapamycin (mTOR), a vital component of signaling pathways involving PI3K/AKT, is an attractive therapeutic target in breast cancer.
Euphemia Y Leung +4 more
doaj +1 more source
adaptive capabilities of the pi3k/akt/mtor pathway in acute myeloid leukemia revealed by the use of selective inhibitors [PDF]
, 2013 Because of its aberrant activation, the PI3K/AKT/mTOR signaling pathway represents a pharmacological target in blast cells from patients with acute myelogenous leukemia (AML).
Bertacchini, Jessika <1980>
core +1 more source
Acta Pharmaceutica Sinica B, 2021 The mammalian target of rapamycin (mTOR)-sterol regulatory element-binding proteins (SREBPs) signaling promotes lipogenesis. However, mTOR inhibitors also displayed a significant side effect of hyperlipidemia.
Ping-Ting Xiao +6 more
doaj +1 more source
Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. [PDF]
PLoS ONE, 2013 The mTOR pathway is aberrantly stimulated in many cancer cells, including pancreatic ductal adenocarcinoma (PDAC), and thus it is a potential target for therapy.
Heloisa P Soares +4 more
doaj +1 more source
Mediation of Anti-Keloid Effects of mTOR Inhibitors by Autophagy-Independent Machinery
International Journal of Dermatology and Venerology, 2021 . Objective:. Blocking mechanistic target of rapamycin (mTOR) activation with mTOR inhibitors has promising therapeutic potential for keloids. However, the precise mechanism of mTOR inhibitors remains unclear. This study was aimed to investigate the role
Meng Jiang +5 more
doaj +1 more source